Navigation Links
Sunesis Reports Financial Results for the Second Quarter 2009
Date:7/29/2009

f 2009, including $1.3 million for lease termination activities and $0.6 million for employee termination costs related to the March 2009 restructuring. For the three and six months ended June 30, 2008, restructuring charges were $4.9 million and $5.2 million, relating primarily to the June 2008 restructuring.
  • Other expense of $21.0 million and $21.1 million was recorded in the three and six months ended June 30, 2009, primarily resulting from non-cash charges of $21.0 million related to the accounting for the private placement.
  • Sunesis reported net losses of $22.9 million and $31.2 million for the three and six months ended June 30, 2009, compared to reported net losses of $13.6 million and $23.2 million for the same periods in 2008.
  • Cash used in operations was $5.8 million and $12.4 million for the three and six month periods ending June 30, 2009, compared to $8.2 million and $18.7 million for the same periods in 2008.

    • About Voreloxin

    Voreloxin is a first-in-class anticancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients and in a Phase 1b/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, as well as in an ongoing Phase 2 single-agent trial in platinum-resistant ovarian cancer.

    About Acute Myeloid Leukemia

    AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates tha
    '/>"/>

    SOURCE Sunesis Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
    2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
    4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
    5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
    6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
    7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
    8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
    9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
    10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
    11. Sunesis to Present at Upcoming Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/17/2013)... 2013 The new Public-Private Partnership (PPP) ... the association’s recent annual meeting drew praise from community ... Kroes, who called the action “a huge step forward ... to European innovation.” , The Board of Stakeholders voted ... Photonics PPP at its 29 April meeting in Brussels, ...
    (Date:5/17/2013)... International, Inc. (NASDAQ: YONG ) ("Yongye" or ... crop nutrient products in the People,s Republic ... 16, 2013, the special committee (the "Special Committee") of ... provided a letter (the "Letter") issued by Abax Global ... to Full Alliance International Limited ("Full Alliance"). The Letter, ...
    (Date:5/17/2013)... 17, 2013 The paradigm of ‘one ... systems that can help predict the adverse and therapeutic ... Stepaniants, Head of Computational Biology at the Genomics Laboratory, ... to ensure high-quality genomics when used as part of ... to complex data sets to identify key clinical targets ...
    (Date:5/17/2013)... Tooth decay is an epidemic in American children with 50% ... World Health Organization says that worldwide, 60–90% of ... are the long-term effects of this transmissible infection? , ... oral bacterial imbalance and serious systemic issues like heart disease. ... also 100% preventable? Answer: there has been no way to ...
    Breaking Biology Technology:SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3
    ... Milestones, CRANBURY, N.J., Nov. 3 Amicus Therapeutics,(Nasdaq: ... third quarter of,2008. On a reported basis calculated in ... a net loss,attributable to common stockholders of $0.36 per ... three months ended September 30, 2008. As of,September 30, ...
    ... Nov. 3 Biomoda, Inc. (OTC,Bulletin Board: BMOD) ... announced today that BUYINS.NET, http://www.buyins.net, is initiating ... data to October 2008. From November 2006 to ... BMOD have traded,for a total dollar value of ...
    ... and GUELPH, Ontario, Nov. 3 LI-COR,Biosciences ... agreement to,distribute LI-COR biotechnology products in Canada ... local presence of Mandel Scientific skilled staff, ... enhance our ability to serve,our Canadian customers," ...
    Cached Biology Technology:Amicus Therapeutics Announces Third Quarter 2008 Financial Results 2Amicus Therapeutics Announces Third Quarter 2008 Financial Results 3Amicus Therapeutics Announces Third Quarter 2008 Financial Results 4Amicus Therapeutics Announces Third Quarter 2008 Financial Results 5Amicus Therapeutics Announces Third Quarter 2008 Financial Results 6Amicus Therapeutics Announces Third Quarter 2008 Financial Results 7Amicus Therapeutics Announces Third Quarter 2008 Financial Results 8Amicus Therapeutics Announces Third Quarter 2008 Financial Results 9Amicus Therapeutics Announces Third Quarter 2008 Financial Results 10Amicus Therapeutics Announces Third Quarter 2008 Financial Results 11Biomoda, Inc. (BMOD) SqueezeTrigger Price is $0.27. Approximately 1 Million Shares Shorted Since November 2006 According to Buyins.net Research Report 2Biomoda, Inc. (BMOD) SqueezeTrigger Price is $0.27. Approximately 1 Million Shares Shorted Since November 2006 According to Buyins.net Research Report 3Biomoda, Inc. (BMOD) SqueezeTrigger Price is $0.27. Approximately 1 Million Shares Shorted Since November 2006 According to Buyins.net Research Report 4LI-COR Biosciences and Mandel Scientific Company Inc. Announce Distribution Agreement 2
    (Date:5/17/2013)... The AGA Research Foundation announced a new grant ... the gut microbiota, one of today,s most exciting areas ... The AGA Research Awards Panel selected Andrew T. Chan, ... and Harvard Medical School, Boston, as the 2013 AGA-Elsevier ... receive $25,000 of funding, commencing in July 2013, to ...
    (Date:5/17/2013)... May 17, 2013, Shenzhen, China---- Why Tibetan antelope ... Qinghai-Tibetan Plateau? In a collaborative research published in ... BGI, and other institutes provide evidence that some ... adaption to harsh highland environments. The data in ... specific genetic mechanisms and the biology of other ...
    (Date:5/16/2013)... a commitment to the support of underrepresented minority ... Foundation has announced the inaugural AGA Investing in ... by the National Institute of Diabetes and Digestive ... underrepresented minority students to further their research careers ... establishing this new award, AGA demonstrates its commitment ...
    Breaking Biology News(10 mins):New gut microbiome research to explore red meat -- colorectal cancer pathway 2The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2Underrepresented minority students receive fellowships in digestive disease and nutrition research 2
    ... at Schepens Eye Research Institute, an affiliate of Harvard ... inside blood vessel cells that controls angiogenesis (new blood ... and off by the balance between two enzymes (known ... of the same lipid membrane to fulfill opposite missions, ...
    ... Institutes of Health today provided the clearest picture yet of ... genes associated with an increased risk of breast cancer. The ... 2 (BRCA2). In addition, the study identified key predictors for ... mutations. , Each year, approximately 200,000 women in the ...
    ... a Saint Louis University vaccine researcher scrutinizes what in ... available anthrax vaccine. , This new type of anthrax ... according to peer-reviewed research published in Vaccine . ... given to 100 volunteers at four sites around the ...
    Cached Biology News:Schepens scientists are first to discover angiogenesis switch inside blood vessel cells 2Schepens scientists are first to discover angiogenesis switch inside blood vessel cells 3New findings offer more complete view of breast cancer gene mutations in US population 2New findings offer more complete view of breast cancer gene mutations in US population 3
    ... Thermo's orbital shaker stands ... a more ergonomic height, and ... Purpose-built from welded tubular steel, ... to support the weight and ...
    ... 5'G AATTC3' 3'CTTAA G5' Inactivation Conditions: Heat inactivation ... Storage Conditions: 10mM Tris-HCl (pH 7.5), 100mM KCl, ... BSA, 50% glycerol. Shipping and Storage: Shipped on ... unit is defined as the amount of enzyme ...
    ... experiment based analysis package designed with easy ... and powerful functionality., Image acquisition interface is ... easy image capture. Sequential and dynamic ... Saturation Warning Single ...
    ... stainless-steel shaker flask clips, purpose-designed to firmly ... All clips are equipped with a top ... include a bottom retainer spring, and silicon ... expensive glassware. Clips include the required ...
    Biology Products: